TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HeraMED Ltd. ( (AU:HMD) ) has shared an update.
HeraMED Limited has reported significant progress in its third-quarter activities for fiscal year 2025, including a successful $1.98 million capital raise and advancements in U.S. commercial agreements. The company is finalizing two pivotal agreements with a global health-technology leader and a major U.S. health system, which are expected to enhance its market positioning and scalability in the U.S. market. Additionally, HeraMED has launched an AI and product strategy, including the AI Clinician Assistant and predictive-modeling initiatives, aimed at strengthening its innovation pipeline and creating new commercial pathways. The company is also advancing its research project with RMIT and Digital Health CRC, focusing on AI-driven predictive maternity care for culturally and linguistically diverse populations.
More about HeraMED Ltd.
HeraMED Limited is a medical data and technology company focused on the digital transformation of maternity care. The company offers the HeraCARE platform, which provides digital health solutions for women’s health, including maternity care. HeraMED is expanding its focus to broader women’s health technology, leveraging data accumulation and AI-driven predictive models.
Average Trading Volume: 2,488,006
Technical Sentiment Signal: Buy
Current Market Cap: A$34.39M
See more insights into HMD stock on TipRanks’ Stock Analysis page.